Fornos 2006.

Study characteristics
Methods	A pharmacotherapy follow‐up program in patients with type‐2 diabetes in community pharmacies in Spain Patient RCT, conducted in community pharmacies in Pontevedra, Spain Two arms: 1. Control (control arm) and 2. Intervention (intervention arm)
Participants	Control arm N: 56 Intervention arm N: 58 Diabetes type: type 2 Mean age: 63.7 ± 10.7 % Male: 42.9 Longest follow‐up: 13 months
Interventions	Control arm: None Intervention arm: 1) Case management 2) Patient education
Outcomes	1) HbA1c, mean % (SD) Control arm: pre 7.8 (1.7), post 8.5 (1.9) Intervention arm: pre 8.4 (1.8), post 7.9 (1.7) 2) SBP, mean mmHg (SD) Control arm: pre 148.0 (18.9), post 150.0 (19.9) Intervention arm: pre 143.0 (20.3), post 135.0 (16.4) 3) DBP, mean mmHg (SD) Control arm: pre 82.2 (11.1), post 82.1 (9.3) Intervention arm: pre 80.2 (9.1), post 78.2 (8.4) 4) LDL, mean mg/dL (SD) Control arm: pre 136.0 (40.2), post 133.0 (41.1) Intervention arm: pre 141.0 (43.1), post 126.0 (40.5)
Funding source	We should also like to thank Bayer Spain, the Official College of Pharmacist of Pontevedra and the Pharmaceutical Northwest Wholesaler Cooperative (Cofano) for their financial support.
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Information not available.
Allocation concealment (selection bias)	Unclear risk	Information not available.
Patient's baseline characteristics (selection bias)	Low risk	Information not available.
Patient's baseline outcomes (selection bias)	Low risk	Information not available.
Incomplete outcome data (attrition bias)	Low risk	Information not available.
Blinding of participants and personnel (performance bias) and of outcome assessors (detection bias)	Low risk	Information not available.
Selective reporting (reporting bias)	Low risk	Information not available.
Risk of contamination (other bias)	Unclear risk	Information not available.
Other bias	Unclear risk	Information not available.